Austar Lifesciences Limited

SEHK:6118 Stock Report

Market Cap: HK$276.8m

Austar Lifesciences Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Mars Ho

Chief executive officer

CN¥935.0k

Total compensation

CEO salary percentage98.3%
CEO tenure11yrs
CEO ownership66.3%
Management average tenure10.6yrs
Board average tenure10.6yrs

Recent management updates

We Think Shareholders May Want To Consider A Review Of Austar Lifesciences Limited's (HKG:6118) CEO Compensation Package

May 24
We Think Shareholders May Want To Consider A Review Of Austar Lifesciences Limited's (HKG:6118) CEO Compensation Package

Recent updates

Austar Lifesciences Limited's (HKG:6118) Share Price Boosted 32% But Its Business Prospects Need A Lift Too

Oct 16
Austar Lifesciences Limited's (HKG:6118) Share Price Boosted 32% But Its Business Prospects Need A Lift Too

Investors Aren't Buying Austar Lifesciences Limited's (HKG:6118) Revenues

Aug 28
Investors Aren't Buying Austar Lifesciences Limited's (HKG:6118) Revenues

We Think Shareholders May Want To Consider A Review Of Austar Lifesciences Limited's (HKG:6118) CEO Compensation Package

May 24
We Think Shareholders May Want To Consider A Review Of Austar Lifesciences Limited's (HKG:6118) CEO Compensation Package

Revenues Working Against Austar Lifesciences Limited's (HKG:6118) Share Price Following 30% Dive

Apr 18
Revenues Working Against Austar Lifesciences Limited's (HKG:6118) Share Price Following 30% Dive

Would Austar Lifesciences (HKG:6118) Be Better Off With Less Debt?

Mar 28
Would Austar Lifesciences (HKG:6118) Be Better Off With Less Debt?

Investors Still Aren't Entirely Convinced By Austar Lifesciences Limited's (HKG:6118) Revenues Despite 25% Price Jump

Feb 12
Investors Still Aren't Entirely Convinced By Austar Lifesciences Limited's (HKG:6118) Revenues Despite 25% Price Jump

Market Cool On Austar Lifesciences Limited's (HKG:6118) Revenues

Dec 22
Market Cool On Austar Lifesciences Limited's (HKG:6118) Revenues

We Think Austar Lifesciences (HKG:6118) Has A Fair Chunk Of Debt

Sep 28
We Think Austar Lifesciences (HKG:6118) Has A Fair Chunk Of Debt

Here's Why Austar Lifesciences (HKG:6118) Has A Meaningful Debt Burden

Mar 31
Here's Why Austar Lifesciences (HKG:6118) Has A Meaningful Debt Burden

Austar Lifesciences Limited (HKG:6118) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Sep 19
Austar Lifesciences Limited (HKG:6118) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Is Austar Lifesciences (HKG:6118) A Risky Investment?

Apr 06
Is Austar Lifesciences (HKG:6118) A Risky Investment?

Austar Lifesciences (HKG:6118) Has A Pretty Healthy Balance Sheet

Oct 24
Austar Lifesciences (HKG:6118) Has A Pretty Healthy Balance Sheet

With EPS Growth And More, Austar Lifesciences (HKG:6118) Is Interesting

Sep 27
With EPS Growth And More, Austar Lifesciences (HKG:6118) Is Interesting

If You Like EPS Growth Then Check Out Austar Lifesciences (HKG:6118) Before It's Too Late

May 31
If You Like EPS Growth Then Check Out Austar Lifesciences (HKG:6118) Before It's Too Late

Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly

Mar 31
Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly

Is Now The Time To Put Austar Lifesciences (HKG:6118) On Your Watchlist?

Mar 01
Is Now The Time To Put Austar Lifesciences (HKG:6118) On Your Watchlist?

Austar Lifesciences Limited (HKG:6118) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?

Feb 01
Austar Lifesciences Limited (HKG:6118) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?

Are Austar Lifesciences's (HKG:6118) Statutory Earnings A Good Guide To Its Underlying Profitability?

Jan 11
Are Austar Lifesciences's (HKG:6118) Statutory Earnings A Good Guide To Its Underlying Profitability?

Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly

Dec 21
Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly

Can You Imagine How Jubilant Austar Lifesciences' (HKG:6118) Shareholders Feel About Its 191% Share Price Gain?

Dec 07
Can You Imagine How Jubilant Austar Lifesciences' (HKG:6118) Shareholders Feel About Its 191% Share Price Gain?

Here's What Austar Lifesciences Limited's (HKG:6118) Shareholder Ownership Structure Looks Like

Nov 23
Here's What Austar Lifesciences Limited's (HKG:6118) Shareholder Ownership Structure Looks Like

CEO Compensation Analysis

How has Mars Ho's remuneration changed compared to Austar Lifesciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CN¥19m

Mar 31 2024n/an/a

-CN¥26m

Dec 31 2023CN¥935kCN¥919k

-CN¥33m

Jun 30 2023n/an/a

CN¥51m

Mar 31 2023n/an/a

CN¥78m

Dec 31 2022CN¥895kCN¥880k

CN¥104m

Sep 30 2022n/an/a

CN¥96m

Jun 30 2022n/an/a

CN¥105m

Mar 31 2022n/an/a

CN¥191m

Dec 31 2021CN¥865kCN¥850k

CN¥277m

Sep 30 2021n/an/a

CN¥258m

Jun 30 2021n/an/a

CN¥238m

Mar 31 2021n/an/a

CN¥136m

Dec 31 2020CN¥927kCN¥911k

CN¥33m

Sep 30 2020n/an/a

CN¥25m

Jun 30 2020n/an/a

CN¥17m

Mar 31 2020n/an/a

CN¥12m

Dec 31 2019CN¥918kCN¥902k

CN¥8m

Sep 30 2019n/an/a

CN¥8m

Jun 30 2019n/an/a

CN¥8m

Mar 31 2019n/an/a

CN¥4m

Dec 31 2018CN¥880kCN¥865k

CN¥107k

Compensation vs Market: Mars 's total compensation ($USD127.82K) is below average for companies of similar size in the Hong Kong market ($USD229.90K).

Compensation vs Earnings: Mars 's compensation has increased whilst the company is unprofitable.

CEO

Mars Ho (62 yo)

11yrs

Tenure

CN¥935,000

Compensation

Mr. Kwok Keung Ho, also known as Mars, is the Founder of Austar Lifesciences Limited and serves as its Chairman of the Board and Chief Executive Officer. Mr. Ho is responsible for overseeing the business,...

Leadership Team

NamePositionTenureCompensationOwnership
Kwok Keung Ho
Founderno dataCN¥935.00k66.27%
HK$ 183.4m
Yuewu Chen
Executive Director10.6yrsCN¥2.13mno data
Ning Zhou
Executive Director10.6yrsCN¥1.11mno data
Kin Hung Ho
Executive Director10.6yrsCN¥2.26m7.27%
HK$ 20.1m
Xiangdi Tang
Vice President of Corporate Development4.1yrsno datano data
Yuk Kiu Mak
Company Secretary2.3yrsno datano data

10.6yrs

Average Tenure

58yo

Average Age

Experienced Management: 6118's management team is seasoned and experienced (10.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Kwok Keung Ho
Founder11yrsCN¥935.00k66.27%
HK$ 183.4m
Yuewu Chen
Executive Director10.6yrsCN¥2.13mno data
Ning Zhou
Executive Director10.6yrsCN¥1.11mno data
Kin Hung Ho
Executive Director11yrsCN¥2.26m7.27%
HK$ 20.1m
Lap Kei Cheung
Independent Non-Executive Director10.3yrsCN¥161.00kno data
Oi Kin Leung
Independent Non-Executive Director7.3yrsCN¥161.00kno data
Hoi Shan Chiu
Independent Non-Executive Director10.3yrsCN¥161.00kno data
Lingling Ji
Non-Executive Director10.6yrsCN¥632.00kno data

10.6yrs

Average Tenure

51.5yo

Average Age

Experienced Board: 6118's board of directors are seasoned and experienced ( 10.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/20 11:09
End of Day Share Price 2025/01/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Austar Lifesciences Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Milo LiuBOCOM International Securities Limited
Forrest ChanCCB International Securities Limited
Tsz Man ChanKGI Securities Co. Ltd.